Safety · Label read 2026-08-03
Estradiol patch side effects, with the placebo column
Every other page listing these reactions drops two things the label itself reports: which dose the rate belongs to, and what the placebo arm did. Both are below, transcribed from the Vivelle-Dot (estradiol transdermal system) prescribing information. The short version: headache is the most common reaction at every dose and it runs 23.6% on placebo too, and weight gain has no dose-response at all.
What are estradiol patch side effects?
Estradiol patch side effects are the unwanted effects of a transdermal estrogen system, which fall into two groups: the systemic effects of raising estrogen, and the skin reactions caused by wearing an adhesive. The patch delivers estradiol through the skin at a fixed microgram-per-day rate, so it bypasses the first-pass liver metabolism that oral estrogen goes through, and that difference in route is why the transdermal and oral forms do not carry identical risk profiles. The reactions listed on a patch label are not all caused by the drug: the same trial measures a placebo arm, and for several of the most-searched reactions the placebo rate is close to, or higher than, the drug rate.
Estradiol is a prescription medicine and this page is not medical advice. Compounded estradiol, which several telehealth platforms dispense, is not an FDA-approved product and has no label like the one below. How the estrogen patch works.
Every reaction, every dose, and the placebo arm
From Table 1 of the Vivelle-Dot (estradiol transdermal system)label: reactions reported at 5% or more, regardless of whether the investigator judged them related to the drug. Percentages are the label's own. Read a row across, and read the last column before you react to any of the others.
| Reaction | 0.025 mg/dayn=47 | 0.0375 mg/dayn=130 | 0.05 mg/dayn=103 | 0.075 mg/dayn=46 | 0.1 mg/dayn=132 | Placebon=157 |
|---|---|---|---|---|---|---|
| Weight increasedInvestigations | 8.5%(4) | 3.8%(5) | 1.9%(2) | 4.3%(2) | 0%(0) | 1.9%(3) |
| HeadacheNervous system | 14.9%(7) | 26.9%(35) | 31.1%(32) | 50%(23) | 25.8%(34) | 23.6%(37) |
| Breast tendernessReproductive system and breast | 17%(8) | 7.7%(10) | 7.8%(8) | 6.5%(3) | 12.9%(17) | 0%(0) |
| Intermenstrual bleedingReproductive system and breast | 6.4%(3) | 6.9%(9) | 5.8%(6) | 0%(0) | 10.6%(14) | 4.5%(7) |
| DepressionPsychiatric | 10.6%(5) | 3.1%(4) | 6.8%(7) | 0%(0) | 3%(4) | 3.8%(6) |
| InsomniaPsychiatric | 6.4%(3) | 4.6%(6) | 3.9%(4) | 4.3%(2) | 1.5%(2) | 5.7%(9) |
| NauseaGastrointestinal | 4.3%(2) | 6.2%(8) | 3.9%(4) | 0%(0) | 5.3%(7) | 3.2%(5) |
| ConstipationGastrointestinal | 4.3%(2) | 3.8%(5) | 3.9%(4) | 6.5%(3) | 1.5%(2) | 2.5%(4) |
| Back painMusculoskeletal | 8.5%(4) | 7.7%(10) | 8.7%(9) | 8.7%(4) | 10.6%(14) | 6.4%(10) |
| Hot flushesVascular | 6.4%(3) | 0%(0) | 2.9%(3) | 0%(0) | 0%(0) | 3.8%(6) |
Application-site reactions are reported separately rather than in the table. The label's wording: "Application site erythema and application site irritation were observed in a small number of patients (3.2% or less of patients across treatment groups)." The 0.025 and 0.075 mg/day arms hold 47 and 46 patients, so a single patient moves those percentages by about two points. Treat the small arms as direction, not precision.
Does the patch cause weight gain?
The label does not show a dose-response, and that is the whole answer. Weight increased in 8.5% at 0.025 mg/day and 0% at 0.1 mg/day, with 1.9% on placebo. If estradiol were driving weight gain, the strongest dose would not be the one with zero events in 132 patients. The randomized trial that asked this question directly, the PEPI body-weight analysis, reached the same conclusion on a different design.
The boxed warning on this label is out of date, and we checked
The FDA announced in November 2025 that it was removing the boxed warnings for cardiovascular disease, breast cancer and probable dementia from systemic menopause hormone therapy, and approved the labelling changes in February 2026. The Vivelle-Dot (estradiol transdermal system)label posted on DailyMed still carries the old boxed warning. It is marked "Revised: 11/2023" and its current DailyMed version is dated 2024-07-04, both of which predate the announcement. We read it on 2026-08-03 and it had not been updated.
Neither half of that is safe to round off. The warning has not simply vanished from pharmacy paperwork, because manufacturers update posted labels on their own schedule. And the warning printed on the box you receive may no longer reflect the FDA's current position. If your patch arrives carrying the old text, that is what this gap looks like. What the FDA actually changed.
Who can still send you a patch
Side effects are only half the decision during a shortage, because the alternative to a patch you cannot get is a different route with a different profile. Of the 13 women's-wing providers whose prices we verify, 11 list a patch among their formats: Alloy, Winona, Midi Health, Sesame Care, Hone Health, Hers Menopause, Wisp, Gala Health, Gennev, Elektra Health, Telos RX. Defy Medical and Inner Balance do not offer one at all.
Listing a format is not the same as having stock, and stock moves weekly. Live per-provider patch status and what the shortage actually is, including our own openFDA queries showing the FDA has not listed estradiol as in shortage while ASHP has.
FAQ
Estradiol patch side effects, answered
What are the side effects of the estradiol patch?
The estradiol patch's labelled side effects are the systemic effects of estrogen plus the skin reactions of the adhesive. On the Vivelle-Dot label, the reactions reported at 5% or more across five dose arms are headache, breast tenderness, intermenstrual bleeding, back pain, depression, insomnia, nausea, constipation, hot flushes and weight increase, alongside application site erythema and irritation in 3.2% or fewer patients. Reading those rates without the placebo column overstates most of them: the placebo arm of the same trial (n=157) reported headache at 23.6%, back pain at 6.4% and insomnia at 5.7%. The patch also carries a boxed warning covering endometrial cancer, cardiovascular disorders, probable dementia and breast cancer, which the FDA announced it was removing from systemic menopause hormone therapy in November 2025 with labelling changes approved in February 2026.
Does the estradiol patch cause weight gain?
The label does not show a dose-response for it, which is the shape you would expect if the drug were causing it. On the Vivelle-Dot table, weight increased in 8.5% of patients at 0.025 mg/day (4 of 47), 3.8% at 0.0375, 1.9% at 0.05, 4.3% at 0.075, and 0% at 0.1 mg/day (0 of 132), against 1.9% in the placebo arm (3 of 157). The highest dose produced the lowest rate. Arm sizes are small at the low end, so treat single percentages with care, but a drug that caused weight gain would not put its zero at its strongest dose.
Are patch side effects different from pills?
The route changes two things. The patch adds application-site reactions, which the Vivelle-Dot label reports as erythema and irritation in 3.2% or fewer patients across treatment groups, and pills do not have them. The patch also delivers estradiol through the skin rather than the gut, so it avoids first-pass liver metabolism, which is the mechanism behind the observed difference in venous thromboembolism risk between transdermal and oral estrogen reported in the BMJ 2019 nested case-control study.
Can I still get an estradiol patch during the shortage?
From the roster we price-verify, 11 of 13 women's-wing providers list a patch among their formats: Alloy, Winona, Midi Health, Sesame Care, Hone Health, Hers Menopause, Wisp, Gala Health, Gennev, Elektra Health, Telos RX. Listing a format is not the same as having stock, which moves weekly, so check the live per-provider status on our patch tracker. Defy Medical and Inner Balance do not offer a patch at all.
Sources
- Vivelle-Dot (estradiol transdermal system) prescribing information, Sandoz Inc, DailyMed (label revised 11/2023, DailyMed version 2024-07-04, read 2026-08-03). Table 1 is the source for every rate on this page.
- FDA, approved labeling changes for menopausal hormone therapy products
- Vinogradova et al, Use of hormone replacement therapy and risk of venous thromboembolism, BMJ 2019 (PMID 30626577)
- PEPI trial, hormone therapy and body weight and girths (PMID 9141548)
- The Menopause Society, 2022 hormone therapy position statement (PMID 35797481)
This is general information, not medical advice. Estradiol is a prescription treatment and whether it is right for you, at which dose and by which route, is a decision for you and a licensed clinician. Reviewed by Iacob Pastina.
Gala Health
Sesame Care
Wisp